Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income towards Parent Company (2022 - 2025)

Historic Income towards Parent Company for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$26.7 million.

  • Zentalis Pharmaceuticals' Income towards Parent Company rose 3353.5% to -$26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.0 million, marking a year-over-year decrease of 28341.8%. This contributed to the annual value of -$165.9 million for FY2024, which is 3998.98% up from last year.
  • Zentalis Pharmaceuticals' Income towards Parent Company amounted to -$26.7 million in Q3 2025, which was up 3353.5% from -$26.9 million recorded in Q2 2025.
  • Zentalis Pharmaceuticals' Income towards Parent Company's 5-year high stood at $10.0 million during Q1 2024, with a 5-year trough of -$99.0 million in Q2 2023.
  • In the last 4 years, Zentalis Pharmaceuticals' Income towards Parent Company had a median value of -$52.1 million in 2022 and averaged -$51.0 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first surged by 11642.4% in 2024, then crashed by 58086.65% in 2025.
  • Zentalis Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$48.4 million in 2022, then fell by 26.17% to -$61.0 million in 2023, then increased by 22.24% to -$47.5 million in 2024, then soared by 43.78% to -$26.7 million in 2025.
  • Its Income towards Parent Company was -$26.7 million in Q3 2025, compared to -$26.9 million in Q2 2025 and -$48.3 million in Q1 2025.